Report
Pharma firms closed over $100 billion in biopharma buyouts in the first half of 2026
Reuters says the firms are racing to replace top-selling medicines worth around $400 billion before their patents expire.
TLDR
Reuters reports that pharma firms closed biopharma buyouts worth over $100 billion in the first half of 2026. It says they are racing to replace top-selling medicines worth around $400 billion before their patents expire. Leah Bennett of Concurrent explains the trend in a Reuters video.
Combined views
48.2K
1 Source, first seen ago
18 likes4 comments4 saves5 reposts